Value-Based Cancer Care Issues


November/December 2010, Vol 1, No 6

Reversing Acute Renal Failure

Cancer Quick Takes

In patients with multiple myeloma with light chain–induced renal failure, treatment with a combination known as BDD (bortezomib [Velcade], doxorubicin [Adriamycin], and dexamethasone [Decadron]) resulted in a high rate of myeloma and renal responses that was well tolerated by patients [ Read More ]

AML Trials: Phases and Changes

Cancer Quick Takes

A discussion of new drug development using the example of acute myeloid leukemia (AML)—but that is applicable to a broad range of diseases— outlines the problems inherent in phase 2 clinical trials that may lead to falsepositive results, and how [ Read More ]

Filling in Funds Around NICE Gaps

Value Propositions

The United Kingdom’s (UK) Department of Health has pledged £250 million toward a Cancer Drugs Fund that will pay for new treatments not available in the state-funded health system. An initial £50 million will provide interim coverage for the financial [ Read More ]

Free Is Good, Not Great, When It Comes to Screening

Value Propositions

Removing payment for health insurance deductibles leads to increased, although modest, improvements in the rates of screening for conditions such as cancer and elevated cholesterol (Meeker D, et al. Health Serv Res. 2010. Online doi:10.1111/j.1475-6773.2010.01188.x). The study analyzed preventive screening [ Read More ]

Shedding Tiers for Better Value

Value Propositions

“If evidence supports a better value for clinical and economic choices, and you throw those on a lower tier, that is to motivate member behavior towards the better value choices. Then, if the individual spends more money, it’s by choice, [ Read More ]